PRA Health Sciences

PRA Health Sciences is a contract research organization (CRO) with headquarters in Raleigh, North Carolina that was founded in 1982.[2] In 2013 the company was acquired by Kohlberg Kravis Roberts, which brought the company public in November 2014 and maintained shares until September 2019.[3]

PRA Health Sciences
Public
Traded as
ISINUS69354M1080 
IndustryPharmaceuticals & Biotechnology
Founded1976 (1976)
Charlottesville, Virginia, U.S.
Headquarters,
U.S.
Area served
Worldwide
Key people
Colin Shannon (President and CEO)
Revenue
  • US$ 1.948 billion (2017)[1]
  • US$ 1.580 billion (2016) [1]
Number of employees
17,000+[1]
Websiteprahs.com

In August 2017 the company acquired Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million.[4]

In November 2019 PRA announced it was partnering with Johnson & Johnson pharmaceutical arm Janssen Pharmaceutica in a first-of-its-kind decentralized clinical trial evaluating the drug Invokana (canagliflozin) in adults with heart failure, with preserved or reduced ejection fraction, with or without type 2 diabetes. This landmark study will collect real-world evidence via a mobile clinical trial platform. [5]

PRA's 2018 revenue was US$2.87 billion.[6]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.